Skip to main content
. 2016 Oct 3;7:12914. doi: 10.1038/ncomms12914

Figure 1. Promotion of lung cancer progression by H3F3A overexpression.

Figure 1

(a) Comparison of H3F3A expression in relapsed and non-relapsed lung cancer patients (GSE13213, Tomida et al.29. All: n=117, P=1.1 × 10−2, stage I: n=79, P=8.5 × 10−3, t-test). (b) (GSE31210, Okayama et al.30. All: n=204, P=8.5 × 10−7, stage I: n=162, P=2.0 × 10−6, t-test). (c) Prognosis of two groups of lung cancer patients classified by H3F3A expression (GSE13213, Tomida et al.29. All: n=117, P=3.2 × 10−2, stage I: n=79, P=2.7 × 10−2, log-rank test). (d) (GSE31210, Okayama et al.30. All: n=204, P=9.7 × 10−3 for overall survival, P=6.4 × 10−2 for relapse-free survival; stage I: n=162, P=1.2 × 10−2 for overall survival, P=6.3 × 10−4 for relapse-free survival, log-rank test). Red: high expression group, blue: low expression group.